Difference between revisions of "Emapalumab (Gamifant)"
m |
|||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 11 | + | * 2018-11-20: Initial approval for adult and pediatric (newborn and older) patients with primary [[Hemophagocytic lymphohistiocytosis|hemophagocytic lymphohistiocytosis (HLH)]] with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. ''(Based on NI-0501-04)'' |
== Patient Drug Information== | == Patient Drug Information== | ||
Latest revision as of 02:01, 8 May 2023
General information
Class/mechanism from the NCI Drug Dictionary: A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 2018-11-20: Initial approval for adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. (Based on NI-0501-04)
Patient Drug Information
Also known as
- Code name: NI-0501
- Generic name: emapalumab-lzsg
- Brand name: Gamifant